Rhizochalinin Exhibits Anticancer Activity and Synergizes with EGFR Inhibitors in Glioblastoma In Vitro Models
Rhizochalinin (Rhiz) is a recently discovered cytotoxic sphingolipid synthesized from the marine natural compound rhizochalin. Previously, Rhiz demonstrated high in vitro and in vivo efficacy in various cancer models. Here, we report Rhiz to be highly active in human glioblastoma cell lines as well as in patient-derived glioma-stem like neurosphere models. Rhiz counteracted glioblastoma cell proliferation by inducing apoptosis, G2/M-phase cell cycle arrest, and inhibition of autophagy. Proteomic profiling followed by bioinformatic analysis suggested suppression of the Akt pathway as one of the major biological effects of Rhiz. Suppression of Akt as well as IGF-1R and MEK1/2 kinase was confirmed in Rhiz-treated GBM cells. In addition, Rhiz pretreatment resulted in a more pronounced inhibitory effect of γ-irradiation on the growth of patient-derived glioma-spheres, an effect to which the Akt inhibition may also contribute decisively. In contrast, EGFR upregulation, observed in all GBM neurospheres under Rhiz treatment, was postulated to be a possible sign of incipient resistance. In line with this, combinational therapy with EGFR-targeted tyrosine kinase inhibitors synergistically increased the efficacy of Rhiz resulting in dramatic inhibition of GBM cell viability as well as a significant reduction of neurosphere size in the case of combination with lapatinib. Preliminary in vitro data generated using a parallel artificial membrane permeability (PAMPA) assay suggested that Rhiz cannot cross the blood brain barrier and therefore alternative drug delivery methods should be used in the further in vivo studies. In conclusion, Rhiz is a promising new candidate for the treatment of human glioblastoma, which should be further developed in combination with EGFR inhibitors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Molecular pharmaceutics - 20(2023), 10 vom: 02. Okt., Seite 4994-5005 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dyshlovoy, Sergey A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.10.2023 Date Revised 25.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1021/acs.molpharmaceut.3c00217 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362305552 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362305552 | ||
| 003 | DE-627 | ||
| 005 | 20231226090947.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acs.molpharmaceut.3c00217 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1207.xml |
| 035 | |a (DE-627)NLM362305552 | ||
| 035 | |a (NLM)37733943 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dyshlovoy, Sergey A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rhizochalinin Exhibits Anticancer Activity and Synergizes with EGFR Inhibitors in Glioblastoma In Vitro Models |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2023 | ||
| 500 | |a Date Revised 25.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Rhizochalinin (Rhiz) is a recently discovered cytotoxic sphingolipid synthesized from the marine natural compound rhizochalin. Previously, Rhiz demonstrated high in vitro and in vivo efficacy in various cancer models. Here, we report Rhiz to be highly active in human glioblastoma cell lines as well as in patient-derived glioma-stem like neurosphere models. Rhiz counteracted glioblastoma cell proliferation by inducing apoptosis, G2/M-phase cell cycle arrest, and inhibition of autophagy. Proteomic profiling followed by bioinformatic analysis suggested suppression of the Akt pathway as one of the major biological effects of Rhiz. Suppression of Akt as well as IGF-1R and MEK1/2 kinase was confirmed in Rhiz-treated GBM cells. In addition, Rhiz pretreatment resulted in a more pronounced inhibitory effect of γ-irradiation on the growth of patient-derived glioma-spheres, an effect to which the Akt inhibition may also contribute decisively. In contrast, EGFR upregulation, observed in all GBM neurospheres under Rhiz treatment, was postulated to be a possible sign of incipient resistance. In line with this, combinational therapy with EGFR-targeted tyrosine kinase inhibitors synergistically increased the efficacy of Rhiz resulting in dramatic inhibition of GBM cell viability as well as a significant reduction of neurosphere size in the case of combination with lapatinib. Preliminary in vitro data generated using a parallel artificial membrane permeability (PAMPA) assay suggested that Rhiz cannot cross the blood brain barrier and therefore alternative drug delivery methods should be used in the further in vivo studies. In conclusion, Rhiz is a promising new candidate for the treatment of human glioblastoma, which should be further developed in combination with EGFR inhibitors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a EGFR | |
| 650 | 4 | |a anticancer | |
| 650 | 4 | |a glioblastoma | |
| 650 | 4 | |a marine natural compounds | |
| 650 | 4 | |a rhizochalinin | |
| 650 | 4 | |a synergism | |
| 650 | 7 | |a rhizochalinin |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins c-akt |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a ErbB Receptors |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a EGFR protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Hauschild, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Venz, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Krisp, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Kolbe, Katharina |e verfasserin |4 aut | |
| 700 | 1 | |a Zapf, Svenja |e verfasserin |4 aut | |
| 700 | 1 | |a Heinemann, Sarina |e verfasserin |4 aut | |
| 700 | 1 | |a Fita, Krystian D |e verfasserin |4 aut | |
| 700 | 1 | |a Shubina, Larisa K |e verfasserin |4 aut | |
| 700 | 1 | |a Makarieva, Tatyana N |e verfasserin |4 aut | |
| 700 | 1 | |a Guzii, Alla G |e verfasserin |4 aut | |
| 700 | 1 | |a Rohlfing, Tina |e verfasserin |4 aut | |
| 700 | 1 | |a Kaune, Moritz |e verfasserin |4 aut | |
| 700 | 1 | |a Busenbender, Tobias |e verfasserin |4 aut | |
| 700 | 1 | |a Mair, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Moritz, Manuela |e verfasserin |4 aut | |
| 700 | 1 | |a Poverennaya, Ekaterina V |e verfasserin |4 aut | |
| 700 | 1 | |a Schlüter, Hartmut |e verfasserin |4 aut | |
| 700 | 1 | |a Serdyuk, Volodymyr |e verfasserin |4 aut | |
| 700 | 1 | |a Stonik, Valentin A |e verfasserin |4 aut | |
| 700 | 1 | |a Dierlamm, Judith |e verfasserin |4 aut | |
| 700 | 1 | |a Bokemeyer, Carsten |e verfasserin |4 aut | |
| 700 | 1 | |a Mohme, Malte |e verfasserin |4 aut | |
| 700 | 1 | |a Westphal, Manfred |e verfasserin |4 aut | |
| 700 | 1 | |a Lamszus, Katrin |e verfasserin |4 aut | |
| 700 | 1 | |a von Amsberg, Gunhild |e verfasserin |4 aut | |
| 700 | 1 | |a Maire, Cecile L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular pharmaceutics |d 2004 |g 20(2023), 10 vom: 02. Okt., Seite 4994-5005 |w (DE-627)NLM154556807 |x 1543-8392 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2023 |g number:10 |g day:02 |g month:10 |g pages:4994-5005 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acs.molpharmaceut.3c00217 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2023 |e 10 |b 02 |c 10 |h 4994-5005 | ||